RS
MRSN

R Squared’s Mersana Therapeutics MRSN Stock Holding History

R Squared’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,889
Closed -$14K – 647
2025
Q2 		$14K Buy
+1,889
New +$16.6K 0.01% 453
2025
Q1 		– Sell
-42
Closed -$1.52K – 1027
2024
Q4 		$1.52K Buy
+42
New +$2.17K ﹤0.01% 1488

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
AV
Alamea Verwaltungs Edison, New Jersey $125M AUM 27.56% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

R Squared's MRSN Position: Q3 2025 in Review

R Squared sold out of Mersana Therapeutics (MRSN) in Q3 2025, closing a stake of 1,889 shares — an estimated $14K sold.

R Squared first reported a position in MRSN in Q4 2024 and held it in 2 quarters. The position peaked at $14K in Q2 2025. 49 funds tracked by Wall St. Rank hold MRSN as of Q3 2025.

  • R Squared reported no remaining Mersana Therapeutics position as of Q3 2025 after selling out during the quarter.
  • R Squared sold 1,889 Mersana Therapeutics shares in Q3 2025, an estimated $14K.
  • R Squared first reported a position in Mersana Therapeutics in Q4 2024 and held it in 2 quarters.
  • R Squared's Mersana Therapeutics position peaked at $14K in Q2 2025.
  • 49 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2025.

Based on R Squared's 13F filing for Q3 2025, filed 12 Nov 2025.